Drug Trial Radar · NCT06569355
A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population
Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Dec 27, 2023
Primary completion
Jul 13, 2024
Study completion Aug 1, 2024
Sponsor
- Lead sponsor
- Vincentage Pharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the study is to assess how VCT220 tablets affect the bodyweight when used once daily in obese or overweight adult participants Qualified participants will be randomly assigned to one of four groups using a computerized system. Participants will get VCT220 or placebo tablets for 16 weeks and will need to take tablets each morning. Participants will have 7 clinic visits and a final follow-up visit approximately 14 days after the last study intervention administration.
Conditions
- Obesity
- Overweight
Interventions
VCT220Drug
A small molecule GLP-1R agonist tablet, orally administration, once daily
PlaceboDrug
Placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weightTime frame: From baseline (week 1) to week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.